Oculis Holding AG (NASDAQ:OCS - Get Free Report) shares gapped down prior to trading on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $18.40, but opened at $17.49. Oculis shares last traded at $18.83, with a volume of 4,718 shares.
The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.
Analyst Ratings Changes
A number of analysts recently commented on OCS shares. Chardan Capital reaffirmed a "buy" rating and set a $28.00 price target on shares of Oculis in a research report on Thursday. HC Wainwright decreased their price target on Oculis from $30.00 to $29.00 and set a "buy" rating for the company in a research report on Thursday. Finally, Robert W. Baird increased their price objective on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a report on Thursday.
Get Our Latest Research Report on Oculis
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of OCS. Geode Capital Management LLC grew its holdings in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after acquiring an additional 1,800 shares during the period. Bellevue Group AG purchased a new position in shares of Oculis during the 4th quarter worth approximately $170,000. Bank of America Corp DE grew its holdings in shares of Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after acquiring an additional 10,667 shares during the period. XTX Topco Ltd purchased a new position in shares of Oculis during the 4th quarter worth approximately $225,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Oculis in the 4th quarter worth approximately $389,000. Institutional investors own 22.30% of the company's stock.
Oculis Price Performance
The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a market cap of $760.26 million, a PE ratio of -9.73 and a beta of 0.02. The firm has a 50 day moving average of $20.89 and a two-hundred day moving average of $16.89.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Recommended Stories
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
